MBX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MBX Biosciences Inc is not a strong buy for a beginner, long-term investor at this time. While there is positive analyst sentiment and potential for future growth, the technical indicators, financial performance, and lack of immediate catalysts do not support a compelling entry point currently.
The MACD is negative and expanding, RSI is neutral at 37.407, and moving averages are converging, indicating no clear upward trend. The stock is trading near its support level of 34.73, with resistance at 40.052.
Analysts have issued positive ratings with price targets significantly above the current price, citing undervaluation and strong industry fundamentals. Upcoming Phase 1b data for its obesity drug MBX 4291 in Q4 2026 could act as a long-term catalyst.
Goldman Sachs issued a Sell rating with a $18 price target, citing concerns about the platform's validity beyond canvuparatide. The stock is currently in a pre-market decline, and technical indicators do not show bullish momentum.
In Q3 2025, the company reported no revenue growth, a net income loss of $21.6M (though improved YoY by 19.16%), and an EPS of -0.63, up 16.67% YoY. The company remains unprofitable with no gross margin.
Analyst sentiment is mostly positive, with multiple Buy ratings and price targets ranging from $50 to $88. However, Goldman Sachs issued a Sell rating with a $18 price target, creating mixed sentiment.
